about
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized mya...
Read More
711.07
4.66
(0.66%)
246.4K
XNAS Volume
XNAS 03 Sep, 2025 1:28 PM (EDT)
Board Meeting
The next board meeting for Argen X SE - ADR is on 08 Sep 2025 for the purpose of argenx Morgan Stanley 23rd Annual Global Healthcare Conference 2025
See details
Medium Financial Strength
Mid Valuation
Technically Moderately Bullish
Turnaround Potential
These stocks may be affordable or expensive due to their medium quality and a good technical scoring. However, their reasonable financials successfully attract investors.
View Similar
Embed DVM
Argen X SE ADR Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..